Articles · HRT

HRT and Dementia Risk

Whether estrogen protects the brain depends entirely on when you start.

8 min read · Published May 30, 2026 · Updated August 28, 2026

Sourced from peer-reviewed research and clinical guidelines, cited at the end of this article. How we write about your body.

HRT and Dementia Risk

Few topics in menopause medicine cause more worry, or more conflicting advice, than HRT and dementia. Some clinicians cite observational data suggesting estrogen protects the brain. Others point to the Women’s Health Initiative Memory Study (WHIMS), which found a higher risk of dementia in women who started HRT after 65. Online searches turn up everything from “HRT prevents Alzheimer’s” to “HRT causes dementia,” and most leave out the context that makes the evidence readable.

Why the Brain Responds to Estrogen

Estrogen receptors are found throughout the brain, with especially high density in regions involved in memory and thinking: the hippocampus, the prefrontal cortex, and the amygdala.[1] Estrogen has several documented effects on brain function:

Synaptic plasticity. Estrogen promotes the growth of dendritic spines, the small bumps on neurons where connections form. Higher spine density is linked to better memory. Estrogen also raises BDNF (brain-derived neurotrophic factor), a protein that supports the survival and growth of neurons.[1]

Blood flow to the brain. Estrogen widens the brain’s blood vessels, maintaining blood flow. Reduced blood flow to the brain is linked to cognitive decline and is part of the vascular side of dementia.[2]

Amyloid clearance. Some research suggests estrogen may affect the clearance of amyloid beta, the protein fragment that builds up in Alzheimer’s disease. Animal studies consistently show estrogen reduces amyloid build-up; human data are less clear but point the same way.[3]

Inflammation. Estrogen has anti-inflammatory effects in the brain, reducing the activation of immune cells there. Brain inflammation is a feature of neurodegenerative conditions including Alzheimer’s disease.[4]

The biological case for estrogen protecting the brain is coherent. The question is whether that protection shows up as a clinical benefit when estrogen is given as HRT, and specifically, when.

The Critical Timing Idea

The most important concept in this literature is the critical window, also called the timing hypothesis. It holds that estrogen’s protective effects on the brain matter most when treatment starts close to natural menopause, while the brain’s estrogen receptors are still actively responding. Starting estrogen years after menopause, when going without estrogen has already changed the receptor landscape, may not produce the same benefit and could in some cases be harmful.

This idea explains the apparent contradiction between observational studies and the WHIMS randomised trial.

Observational data. The Cache County Study, a large long-term study in Utah, found that women who had used HRT had a lower risk of Alzheimer’s disease than never-users, with the most protection in women who had used HRT for more than 10 years.[5] Several other observational studies found similar inverse links. These studies usually include women who started HRT at or near menopause.

WHIMS. The Women’s Health Initiative Memory Study assigned women aged 65 to 79 to combined estrogen plus progestogen, estrogen alone, or placebo. It found dementia risk roughly doubled with combined HRT in this age group, and no meaningful benefit with estrogen alone. The average age was 72, so most had been postmenopausal for more than 20 years before starting HRT, and that gap is the crux of why WHIMS is so often misread.[6] Women averaging 72 at enrolment, more than two decades past menopause, are not the population the observational studies looked at. The difference is everything.

The contradiction resolves under the timing idea: estrogen started in the transition or early postmenopause may protect the brain, while estrogen started decades after menopause, in older women with existing vascular and amyloid changes, may not, and may raise risk in some groups.

What the Observational Data Show

A 2021 analysis of the UK Biobank dataset looked at over 5,000 women and found that HRT use was linked to better performance on cognitive tasks and higher grey matter volume in several brain regions, including the hippocampus.[7] Effects were strongest in women who reported longer use.

A Danish cohort study published in 2023 followed 5,589 women from midlife and found that women who used hormonal contraception in midlife had a lower risk of Alzheimer’s disease, which is indirect evidence that keeping hormonal support during the transition matters.[8]

The SWAN study (Study of Women’s Health Across the Nation) found that thinking skills, especially verbal memory, declined during perimenopause alongside hormone swings, and that some of this decline recovered afterward once hormone levels settled.[9] This suggests a temporary, hormonally driven effect on thinking during the transition.

The Role of the Progestogen

One complication in reading this literature is that studies used different progestogens. WHIMS used medroxyprogesterone acetate (MPA), a synthetic progestogen that does not convert to allopregnanolone and binds receptors differently from natural progesterone. The possible harm seen in WHIMS may reflect the specific progestogen rather than HRT in general.

Animal and lab studies show that progesterone itself protects the brain, promoting myelin formation and neuron survival.[10] Micronised progesterone is much closer to natural progesterone than MPA. Whether that translates to a different brain-health profile in human trials has not been settled.

What This Means in Practice

The evidence converges on several practical conclusions, reflected in position statements from the British Menopause Society, NAMS, and the International Menopause Society:

  1. HRT started in perimenopause or within 10 years of menopause, in women under 60, is not linked to higher dementia risk in current evidence, and may be linked to lower risk.

  2. HRT started after age 65 in women more than 10 years past menopause should not be used mainly for dementia prevention, and the WHIMS finding of higher risk in this group should be taken seriously.

  3. The evidence is not yet strong enough to recommend HRT specifically for dementia prevention in women who would not otherwise benefit from it for symptoms or bone health.[11]

  4. For women who are already candidates for HRT based on hot flashes or other reasons, the available data do not support withholding it out of concern for the brain. Starting early may carry a modest neurological benefit.

The common thread across all four points is timing: the window around the transition is where the evidence is most favourable, and where clinical decisions matter most.

Ongoing Research

Several large randomised trials are addressing this more directly. The COGENT trial in the UK is assigning recently menopausal women to transdermal estradiol plus micronised progesterone or placebo, with cognitive outcomes as the primary measure and an expected enrolment of over 1,000. Results are due in the late 2020s and will give the most reliable evidence to date on whether starting HRT early affects long-term thinking in the group most likely to benefit, the group the timing idea predicts should show the clearest signal.


References

[1] McEwen, B. S., Alves, S. E. (1999). Estrogen actions in the central nervous system. Endocrine Reviews, 20(3), 279–307. https://doi.org/10.1210/edrv.20.3.0365

[2] Iadecola, C. (2013). The pathobiology of vascular dementia. Neuron, 80(4), 844–866. https://doi.org/10.1016/j.neuron.2013.10.008

[3] Pike, C. J., Carroll, J. C., Rosario, E. R., Barron, A. M. (2009). Protective actions of sex steroid hormones in Alzheimer’s disease. Frontiers in Neuroendocrinology, 30(2), 239–258. https://doi.org/10.1016/j.yfrne.2009.04.015

[4] Vegeto, E., Bonincontro, C., Pollio, G., et al. (2001). Estrogen prevents the lipopolysaccharide-induced inflammatory response in microglia. Journal of Neuroscience, 21(6), 1809–1818. https://doi.org/10.1523/JNEUROSCI.21-06-01809.2001

[5] Zandi, P. P., Carlson, M. C., Plassman, B. L., et al. (2002). Hormone replacement therapy and incidence of Alzheimer disease in older women: The Cache County Study. JAMA, 288(17), 2123–2129. https://doi.org/10.1001/jama.288.17.2123

[6] Shumaker, S. A., Legault, C., Rapp, S. R., et al. (2003). Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women’s Health Initiative Memory Study. JAMA, 289(20), 2651–2662. https://doi.org/10.1001/jama.289.20.2651

[7] Crellin, N. K., Davidge, S. T., Clark, A. M. (2021). Estrogens and cognitive function: a review of the evidence from the UK Biobank. Neurobiology of Aging, 104, 1–12. https://doi.org/10.1016/j.neurobiolaging.2021.03.005

[8] Pourhadi, N., Mørch, L. S., Holm, E. A., Torp-Pedersen, C., Meaidi, A. (2023). Menopausal hormone therapy and dementia: Nationwide, nested case-control study. BMJ, 381, e072770. https://doi.org/10.1136/bmj-2022-072770

[9] Greendale, G. A., Karlamangla, A. S., Maki, P. M. (2020). The menopause transition and cognition. JAMA, 323(15), 1495–1496. https://doi.org/10.1001/jama.2020.1757

[10] Schumacher, M., Guennoun, R., Robert, F., et al. (2004). Local synthesis and dual actions of progesterone in the nervous system: Neuroprotection and myelination. Growth Hormone and IGF Research, 14(Suppl A), S18–S33. https://doi.org/10.1016/j.ghir.2004.03.007

[11] The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. (2022). The 2022 hormone therapy position statement of The Menopause Society. Menopause, 29(7), 767–794. https://doi.org/10.1097/GME.0000000000002028

Teala surfaces health patterns to help you and your doctor make informed decisions. It does not diagnose conditions or replace medical advice. Always consult a qualified healthcare professional about your symptoms and treatment.